Coulter Partners was very pleased to partner recently with Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, to secure the appointment of Rudolf Baumgartner, M.D., as Chief Medical Officer and Head of Clinical Development. Dr. Baumgartner brings more than 20 years of experience leading multiple pharmaceutical development programs from discovery through approval and launch, in both large and small pharmaceutical companies.
“Rudi’s clinical development expertise will be critical as Saniona advances its’ mid/late stage development of Tesomet in two rare eating disorders: Prader Willi Syndrome and hypothalamic obesity,” said Rami Levin, President and Chief Executive Officer of Saniona. “As we pursue our End of Phase 2 meeting with the FDA and determine the regulatory path for bringing Tesomet to patients in these indications, we look forward to Rudi’s insights and expertise to build out the clinical development team and progress our programs through to commercialization. Thank you, to the team at Coulter Partners, for their outstanding professional support in achieving this appointment.”
“This is an exciting time to join the Saniona team, as the company builds on its strong scientific roots to become a U.S.-based biopharmaceutical company preparing for late-stage trials of Tesomet in two rare diseases,” said Dr. Baumgartner. “The two diseases for which we are evaluating Tesomet, hypothalamic obesity and Prader-Willi Syndrome, both lack approved treatment options and represent significant unmet needs for patients and their families.”
Dr. Baumgartner is a physician-scientist with a proven track record of leading cross-functional teams through multiple development programs from Investigational New Drug (IND) applications through New Drug Application (NDA) submissions and product approvals. Trained in basic immunology, he brings to Saniona significant expertise across a broad array of therapeutic areas, including inflammation and auto-immune diseases. Most recently, he served as Chief Medical Officer for the Flatley Discovery lab, a non-profit foundation working in the rare disease space of Cystic Fibrosis. Prior to that, he was the Executive Vice President and Chief Medical Officer for Inotek Pharmaceuticals, where he was instrumental in writing the S1 and co-leading the company’s IPO. At Inotek Pharmaceuticals, he oversaw clinical development and operations, medical affairs, regulatory affairs, biostatistics, preclinical development, and intellectual property. Before Inotek, Dr. Baumgartner held senior-level development positions at Sepracor and Merck & Co. He began his medical career as a clinician-scientist at the National Institutes of Health (NIH), in the Laboratory of Molecular Immunology at the National Heart, Lung, and Blood Institute (NHLBI). He completed his M.D. at Pennsylvania State University, his residency in Internal Medicine at the University of Michigan, and his fellowship in Pulmonary and Critical Care Medicine at Johns Hopkins University.
Saniona is a rare disease biopharmaceutical company focused on research, development and commercialization of treatments for the central nervous system. The company has four programs in clinical development. Saniona intends to develop and commercialize treatments for rare disease indications such as Prader-Willi syndrome and hypothalamic obesity on its own. The research is focused on ion channels and the company has a broad portfolio of research programs. Saniona also has out-licensing agreements with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cadent Therapeutics. Saniona is based in Copenhagen, Denmark, and in Boston, US. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION).
For more information about Saniona, please visit www.saniona.com.
LSX - European Lifestars Awards
14 November 2022
Top global hires for large-cap, mid-cap and public companies
07 June 2022
Top hires for VC & PE portfolio companies Q4-2021
25 January 2022
Top hires for VC & PE portfolio companies Q2-2021
27 July 2021